Majem M - Search Results

1

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.

Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Bustamante Alvarez J, Hummel HD, Dingemans AC, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang T, Martinez P, Anderson ES, Paz-Ares L; DeLLphi-301 Investigators. Ahn MJ, et al. Among authors: majem m. N Engl J Med. 2023 Nov 30;389(22):2063-2075. doi: 10.1056/NEJMoa2307980. Epub 2023 Oct 20. N Engl J Med. 2023. PMID: 37861218 Clinical Trial.

2

SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016).

de Las Peñas R, Blasco A, De Castro J, Escobar Y, García-Campelo R, Gúrpide A, Lopez-Lopez R, Majem M, Rodríguez CA, Virizuela JA. de Las Peñas R, et al. Among authors: majem m. Clin Transl Oncol. 2016 Dec;18(12):1237-1242. doi: 10.1007/s12094-016-1583-0. Epub 2016 Nov 28. Clin Transl Oncol. 2016. PMID: 27896642 Free PMC article.

3

The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.

Bonanno L, Costa C, Majem M, Favaretto A, Rugge M, Rosell R. Bonanno L, et al. Among authors: majem m. Ann Oncol. 2013 Apr;24(4):1130-2. doi: 10.1093/annonc/mdt063. Epub 2013 Feb 20. Ann Oncol. 2013. PMID: 23429864 Free article. No abstract available.

4

Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Delta24RGD.

Majem M, Cascallo M, Bayo-Puxan N, Mesia R, Germa JR, Alemany R. Majem M, et al. Cancer Gene Ther. 2006 Jul;13(7):696-705. doi: 10.1038/sj.cgt.7700940. Epub 2006 Feb 24. Cancer Gene Ther. 2006. PMID: 16498429

5

A phase I clinical and pharmacokinetic study (LIPOTEC - GP PHARM/DOXO 01) of a new liposomal doxorubicin given as 3-week schedule in patients with solid tumors.

Majem M, Salazar R, Garcia M, Clopes A, Muñoz C, Pardo B, Martinez M, Cuadra C, Montes A, Mis R, Savulsky C, Ramon Germa-Lluch J. Majem M, et al. J Liposome Res. 2009;19(4):261-6. doi: 10.3109/08982100902804833. J Liposome Res. 2009. PMID: 19863161 Clinical Trial.

6

Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer.

Salazar R, Navarro M, Losa F, Alonso V, Gallén M, Rivera F, Benavides M, Escudero P, González E, Massutí B, Gómez A, Majem M, Aranda E. Salazar R, et al. Among authors: majem m. Clin Transl Oncol. 2012 Aug;14(8):592-8. doi: 10.1007/s12094-012-0846-7. Epub 2012 Jul 11. Clin Transl Oncol. 2012. PMID: 22855141 Clinical Trial.

7

The oncology acute toxicity unit (OATU): an outpatient facility for improving the management of chemotherapy toxicity.

Majem M, Galán M, Pérez FJ, Muñoz M, Chicote S, Soler G, Navarro M, Martínez-Villacampa M, García del Muro X, Dotor E, Laquente B, Germà JR. Majem M, et al. Clin Transl Oncol. 2007 Dec;9(12):784-8. doi: 10.1007/s12094-007-0140-2. Clin Transl Oncol. 2007. PMID: 18158982

8

Treatment of patients with unresectable squamous head and neck cancer with induction chemotherapy followed by hyperfractionated radiotherapy.

Mesía R, Majem M, Barretina Ginesta MP, Galiana R, Mañós M, Guedea F, Montes A, Monner A, Pérez J, Cardenal F. Mesía R, et al. Among authors: majem m. Cancer Radiother. 2008 Mar;12(2):88-95. doi: 10.1016/j.canrad.2007.09.148. Epub 2007 Dec 21. Cancer Radiother. 2008. PMID: 18155633

9

Phase I/II docetaxel plus concurrent hyperfractionated radiotherapy in locally advanced unresectable head and neck cancer (TAX.ES1.102 study).

Barnadas A, Mesía R, Majem M, Galiana R, López-Pousa A, de Vega JM, Margelí M, Valentí V, Anglada L, Lloansí A, Arellano A. Barnadas A, et al. Among authors: majem m. Clin Transl Oncol. 2011 Apr;13(4):254-60. doi: 10.1007/s12094-011-0650-9. Clin Transl Oncol. 2011. PMID: 21493186 Clinical Trial.

10

Screening for epidermal growth factor receptor mutations in lung cancer.

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M; Spanish Lung Cancer Group. Rosell R, et al. Among authors: majem m. N Engl J Med. 2009 Sep 3;361(10):958-67. doi: 10.1056/NEJMoa0904554. Epub 2009 Aug 19. N Engl J Med. 2009. PMID: 19692684 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

160 results

Search Page